This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Washington Goes to Pot

NEW YORK ( TheStreet) -- Following disastrous comments last week at a House Committee hearing by Drug Czar Michael Boticelli, Tennessee Rep. Steve Cohen introduced a bill called the Unmuzzle the Drug Czar Act of 2014. The bill, H.R. 4046, will amend the Office of National Drug Control Policy Reauthorization Act of 1998 and allow the Drug Czar to study the medicinal uses of a drug listed as a "schedule 1" controlled substance drug.

The drug in question is marijuana, which has been legalized for medicinal use and recreational use in some states. Backers want the Drug Czar to no longer oppose attempts to legalize the use of such a substance.

Last Tuesday, Boticelli, the Office of National Drug Control Policy's (ONDCP) Deputy Director, came under fire for refusing to acknowledge that marijuana was less harmful than heroin or methamphetamine. Boticelli refused to answer questions as to why marijuana was considered more dangerous than cocaine, meth or tobacco, all of which are lower on the ladder of controlled substances.

Rep. Earl Blumenauer of Oregon called Boticelli's refusal to realistically discuss drug use "part of the problem" and suggested the ONDCP was relying on marijuana "propaganda." Rep. Cohen questioned the drug czar's statistics that can be seen in this video and also criticized the office for not addressing the National Institute on Drug Abuse's obstruction of research for medicinal marijuana.

"Every objective study on marijuana has concluded that it poses less harm than alcohol to the consumer and society. Government officials should not be prohibited by law from acknowledging that," said Dan Riffle of the Marijuana Policy Project.

However, in Wednesday's New York Times, Orrin Devinsky and Daniel Friedman, physicians at the NYU Comprehensive Epilepsy Center wrote, "The truth is we lack evidence not only for the efficacy of marijuana, but also for its safety." The physicians said the recent wave of state legislatures approving medical marijuana raises "significant concerns." They agree that marijuana should be changed from a schedule 1 controlled substance and that roadblocks for studies should be removed.

Must ReadColorado Kids Get Legal Pot as New York Doctors Can Barely Study It

The physicians will begin their two-year study in 2014 on the effects of marijuana for epilepsy patients. In order to do the study, they have to keep the product in a 1,200-pound safe in a locked room in a building with an alarm system, since it is designated as a dangerous drug.

Politicians supporting a change in classification aren't necessarily from pot friendly states. Cohen state of Tennessee has only recently introduced a medical marijuana bill for its state and has some of the strictest marijuana penalties. A single gram can send a person to jail for a year with a mandatory fine between $250 and $2,500. Blumenauer's state of Oregon approved medical marijuana in 2013, but voted down recreational marijuana in 2012. As of now there is no legislation written for November's 2014 elections to end marijuana prohibition, but the Oregon lawmakers continue meeting up to March 9.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs